Evidence map›Paper›PMID 39802853›Full record

ReviewEuroasian journal of hepato-gastroenterology

HeberNasvac: Development and Application in the Context of Chronic Hepatitis B.

Julio C Aguilar, Sheikh Mf Akbar, Mamun Al-Mahtab, Md Sakirul I Khan, Carlos A Guzman, Guillermo Fernandez, Jorge A Aguiar, Marie-Louise Michel, Maryline Bourgine, Maria A Marrero and 10 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Euroasian journal of hepato-gastroenterology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Julio C AguilarDepartment of Vaccines, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba.ORCID https://orcid.org/0000-0003-0166-4784
Sheikh Mf AkbarDepartment of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon City, Japan.
Mamun Al-MahtabDepartment of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh.ORCID https://orcid.org/0000-0003-3728-3879
Md Sakirul I KhanDepartment of Research Center for Global and Local Infectious Diseases, Oita University, Oita, Japan.
Carlos A GuzmanDepartment of Vaccinology and Applied Microbiology, Helmholtz Center for Infection Research (HZI), Braunschweig, Germany.
Guillermo FernandezDepartment of Gastroenterology, Abel Santamaría Hospital, Pinar del Rio, Cuba.
Jorge A AguiarDepartment of Vaccines, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba.
Marie-Louise MichelLaboratory of Hepatitis B Virus Pathogenesis, Institut Pasteur, Paris, France.
Maryline BourgineDepartment of Institut Pasteur-TheraVectys Joint Lab, Institut Pasteur Paris, France.
Maria A MarreroDepartment of Clinical Trials, National Coordinating Center for Clinical Trials (CENCEC), Havana, Cuba.
Stephanie TrittelDepartment of Vaccinology and Applied Microbiology, Helmholtz Center for Infection Research (HZI), Braunschweig, Germany.
Thomas EbensenDepartment of Vaccinology and Applied Microbiology, Helmholtz Center for Infection Research (HZI), Braunschweig, Germany.
Peggy RieseDepartment of Vaccinology and Applied Microbiology, Helmholtz Center for Infection Research (HZI), Braunschweig, Germany.
Roger Le GrandDepartment of Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Université Paris-Saclay, Inserm, CEA, Paris, France.
Cecile HerateDepartment of Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Université Paris-Saclay, Inserm, CEA, Paris, France.
Aurelie MaurasDepartment of Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Université Paris-Saclay, Inserm, CEA, Paris, France.
Osamu YoshidaDepartment of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon City, Japan.
Yoichi HiasaDepartment of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon City, Japan.
Eduardo PentonDepartment of Vaccines, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba.
Gerardo E GuillenDepartment of Vaccines, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The immune system plays a central role in controlling acute hepatitis B infection and in patients resolving chronic hepatitis B (CHB). Given that 221 million (75%) of CHB patients reside in low- and middle-income countries, the development of a vaccine with therapeutic properties represents a rational and cost-effective approach more than a romantic endeavor. This review systematically analyzes the key variables related to the safety, efficacy, and effectiveness of CHB treatments. HeberNasvac experience is revisited for addressing the challenges and potentialities of therapeutic vaccines, as well as the current roadblocks in research and development, registration, and large-scale implementation. How to cite this article: Aguilar JC, Akbar SMF, Al-Mahtab M,

Indexed as

AntiviralChronic hepatitisFunctional cureTherapeutic vaccineTherapy

Identifiers

PMID39802853
PMCPMC11714097

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.